Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: China Cross-Border Firm Invests Up to $30M in Clinical Stage Therapeutics & Near Market Ready Devices and Diagnostic Companies

15 Aug

A cross-border life science investment firm focuses on the pharmaceutical, medical device, and diagnostics sectors. In addition to investment, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-30 M, and is currently seeking global opportunities.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Global Japanese Pharmaceutical Seeks Global In-Licensing & Investment Opportunities in CNS and Orphan Indications

15 Aug

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered with a focus on Japan-based academic institutions. In addition, the firm is an active investor into Series A raises and invests up to $1M in initial investment, for which the firm considers global opportunities.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS, orphan disease, and genetically defined platform and asset focused companies with strong emphasis on novel drug discovery platforms. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Hybrid Family Office Invests Up to $100M in Global Life Science Companies Across All Stages of Development

15 Aug

A hybrid family office and operating company with USA offices makes investments ranging from approximately $500,000 to $100 million into companies, and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: